MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Raymond W. Cohen to its Board of Directors. Mr. Cohen has over 40 years of leadership experience in medical technology with a successful track record of scaling commercial operations and creating shareholder value through market leadership and successful exit transactions. “We are thrilled ...

Second-Quarter 2025 Earnings Baxter International Inc. July 31, 2025 1 Forward-Looking Statements This presentation includes forward-looking statements concerning the company's financial results (including the outlook for third-quarter and full-year 2025) and operational (including with respect to the new Vizient partnership), business development and regulatory activities. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actu ...

RUTHERFORD, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced it will participate in the 2025 Association of Diabetes Care and Education Specialists (ADCES) Annual Meeting to be held on August 8-11, 2025 in Phoenix, AZ, as the Company prepares to begin its long-term early feasibility study following successful initial clinical validation. T ...

EARNINGS PRESENTATION Q2 2025 July 31, 2025 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this presentation. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like "will," "believe," "ma ...

BERKELEY, Calif, July 31, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces it has signed a Letter of Intent (LOI) to enter into a distribution agreement in Spain for its Lumee Oxygen platform. The Spanish distributor, Dismeval, S.L., specializes in the distribution of medical and surgical equipment thr ...

业绩总结 - 2025年第二季度调整后的恒定货币收入同比增长1.0%[12] - 2025年第二季度总收入为7.809亿美元，同比增长4.2%[34] - 2025年第二季度GAAP每股收益为2.77美元，同比增长64.3%[38] - 2025年第二季度调整后每股收益为3.73美元，同比增长9.1%[12] - 2025年上半年整体报告收入为14.816亿美元，同比下降0.4%[67] 用户数据 - 2025年第二季度美洲地区销售额为5.257亿美元，报告收入增长1.9%[13] - 2025年第二季度EMEA地区销售额为1.662亿美元，报告收入增长13.0%[13] - 2025年第二季度亚洲地区销售额为8900万美元，报告收入增长2.3%[13] 毛利率与利润 - 2025年第二季度调整后的毛利率为59.7%[12] - 2025年第二季度调整后的营业利润率为26.9%[12] - 2025年第二季度整体毛利率为55.2%[68] - 2025年上半年整体毛利率为55.4%[72] - 2025年调整后毛利率预期为58.75%至59.50%[78] 未来展望 - 2025年GAAP收入增长预期为9.00%至10.00%[41] - 2025年调整后的恒定货币收入增长指导范围提高至7.70%至8.70%[12] - 2025年调整后每股收益预期为13.90至14.30美元，年增长率为(0.8)%至2.1%[41] 新产品与市场扩张 - 2025年第二季度血管通路产品的报告收入为1.855亿美元，同比增长2.4%[66] - 2025年第二季度介入产品的报告收入为1.700亿美元，同比增长20.4%[66] - 2025年第二季度麻醉产品的报告收入为9640万美元，同比下降6.0%[66] - 2025年第二季度手术产品的报告收入为1.140亿美元，同比增长2.5%[66] - 2025年第二季度OEM产品的报告收入为7870万美元，同比下降11.4%[66] 收购与投资 - 收购BIOTRONIK的血管介入业务的初始现金支付为7.04亿欧元[23] 负面信息 - 2025年上半年调整后收入同比下降1.3%[80]

Based in Ireland, Medtronic plc (NYSE: MDT ) is a medical device manufacturer with operations throughout the world. At this time, the company has four reportable segments; Cardiovascular, Medical Surgical, Neurosciences, and Diabetes. However, a few months ago, management announced they would be spinning off theI have a masters degree in Analytics from Northwestern University and a bachelors degree in Accounting. I have worked in the investment arena for over 10 years starting as an analyst and working my w ...

文章核心观点 公司公布2025年第二季度财务业绩，营收和盈利表现良好，收购BIOTRONIK血管介入业务推动全年业绩指引上调，未来将专注业务分离以提升股东价值 [1][3][9] 第二季度财务总结 净营收按报告运营部门划分 - 美洲地区：三个月GAAP净营收5.257亿美元，同比增长1.9%，调整后不变货币基础增长2.0%；六个月GAAP净营收10.014亿美元，同比下降0.8%，调整后不变货币基础下降0.6% [5] - EMEA地区：三个月GAAP净营收1.662亿美元，同比增长13.0%，调整后不变货币基础下降2.1%；六个月GAAP净营收3.174亿美元，同比增长3.5%，调整后不变货币基础下降2.4% [5] - 亚洲地区：三个月GAAP净营收0.89亿美元，同比增长2.3%，调整后不变货币基础增长1.2%；六个月GAAP净营收1.628亿美元，同比下降4.9%，调整后不变货币基础下降4.0% [5] - 合并数据：三个月GAAP净营收7.809亿美元，同比增长4.2%，调整后不变货币基础增长1.0%；六个月GAAP净营收14.816亿美元，同比下降0.4%，调整后不变货币基础下降1.3% [5] 净营收按全球产品类别划分 - 血管通路：三个月GAAP净营收1.855亿美元，同比增长2.4%，调整后不变货币基础增长1.4%；六个月GAAP净营收3.679亿美元，同比增长1.5%，调整后不变货币基础增长1.6% [8] - 介入：三个月GAAP净营收1.7亿美元，同比增长20.4%，调整后不变货币基础增长19.3%；六个月GAAP净营收3.076亿美元，同比增长11.5%，调整后不变货币基础增长11.5% [8] - 麻醉：三个月GAAP净营收0.964亿美元，同比下降6.0%，调整后不变货币基础下降7.6%；六个月GAAP净营收1.83亿美元，同比下降8.0%，调整后不变货币基础下降8.1% [8] - 外科：三个月GAAP净营收1.14亿美元，同比增长2.5%，调整后不变货币基础增长1.4%；六个月GAAP净营收2.198亿美元，同比增长1.4%，调整后不变货币基础增长1.7% [8] - 介入泌尿外科：三个月GAAP净营收0.764亿美元，同比下降8.1%，调整后不变货币基础下降8.3%；六个月GAAP净营收1.474亿美元，同比下降9.5%，调整后不变货币基础下降9.5% [8] - OEM：三个月GAAP净营收0.787亿美元，同比下降11.4%，调整后不变货币基础下降12.4%；六个月GAAP净营收1.426亿美元，同比下降19.2%，调整后不变货币基础下降19.5% [8] - 其他：三个月GAAP净营收0.599亿美元，同比增长43.5%，调整后不变货币基础增长3.5%；六个月GAAP净营收1.133亿美元，同比增长20.3%，调整后不变货币基础增长4.0% [8] 其他财务亮点 - GAAP营收：2025年全年同比增长展望从1.28% - 2.28%上调至9.00% - 10.00% [9] - 调整后不变货币营收：2025年全年同比增长展望从1.00% - 2.00%上调至7.70% - 8.70% [9] - GAAP摊薄后持续经营每股收益：2025年全年展望从6.51 - 6.91美元上调至6.73 - 7.13美元 [10] - 调整后摊薄后持续经营每股收益：2025年全年指引从13.20 - 13.60美元上调至13.90 - 14.30美元，同比下降0.8%至增长2.1% [10] 非GAAP财务指标说明 - 公司提供调整后营收、调整后不变货币营收增长和调整后摊薄每股收益等非GAAP财务指标，用于评估财务表现、决策、资源分配和业绩比较，但不能替代GAAP指标，且可能与其他公司不可比 [19] - 各非GAAP指标调整项目包括重组和合理化费用、减值费用、收购整合和剥离相关项目、分离成本、意大利回报措施、养老金终止及相关费用、欧洲医疗器械法规费用、无形资产摊销费用、ERP实施费用和税务调整等 [24] 财务报表 综合损益表 - 展示了2025年和2024年第二季度及前六个月的营收、成本、费用、利润和每股收益等信息 [52] 综合资产负债表 - 呈现了2025年6月29日和2024年12月31日的资产、负债和股东权益情况 [54] 综合现金流量表 - 反映了2025年和2024年前六个月的经营、投资和融资活动现金流量情况 [57] 公司展望 - 收购BIOTRONIK血管介入业务预计在2025年下半年产生2.04亿美元营收，外汇汇率波动预计全年带来约0.85%的积极影响 [9] - 持续执行价值创造战略，推进业务分离，探索最大化股东价值的方案 [3] 会议信息 - 2025年第二季度投资者电话会议网络直播于7月31日上午8:00 ET开始，可通过公司网站链接观看 [15] - 电话会议音频回放于7月31日上午11:00 ET开始，可通过公司网站或电话获取，美国和加拿大拨打1 800 770 2030，其他地区拨打1 609 800 9909，确认码69028 [16]

For the quarter ended June 2025, Merit Medical (MMSI) reported revenue of $382.46 million, up 13.2% over the same period last year. EPS came in at $1.01, compared to $0.92 in the year-ago quarter.The reported revenue represents no surprise over the Zacks Consensus Estimate of $0 million. With the consensus EPS estimate being $0.86, the EPS surprise was +17.44%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next mov ...

Merit Medical Systems (MMSI) Q2 2025 Earnings Call July 30, 2025 05:00 PM ET Company ParticipantsFred Lampropoulos - Founder, Chairman, CEO & PresidentBrian Lloyd - Chief Legal Officer & Corporate SecretaryRaul Parra - CFO & TreasurerJayson Bedford - MD - Medical TechnologyConference Call ParticipantsJason Bednar - MD & Senior Research AnalystRobert Marcus - Senior AnalystSteven Lichtman - MD & Senior Analyst - Medical DevicesJames Sidoti - AnalystNone - AnalystMike Matson - MD - Senior Equity Research Anal ...